In this podcast, we feature an article about a recent DCAT Benchmarking study, conducted prior to COVID-19, that provides insights on whether biopharma companies and their suppliers believe the deteriorating…
Podcast 13: Pharma Company on the Move: The New AbbVie
In this podcast, we feature an article that examines the new AbbVie, including the key products and expanded manufacturing networking, resulting from its recent acquisition of Allergan. For a text…
Podcast 12: Re-inventing US Pharma Mfg and Supply Chains
In this podcast, we feature an article about the Association for Accessible Medicines’ blueprint to facilitate a repatriation of pharma manufacturing to the US. For the text version of this…
In this podcast, we outline the manufacturing strategies and alliances that are in play to develop and supply treatments and vaccines against COVID-19. For the text version of this article…
In this podcast, we feature an article that examines the effect of COVID-19 on drug development, clinical trials, regulatory review, and new drug approvals. For the text version of this…
Podcast 9: A Top 10 Watch List: Biologics and Biomanufacturing
In this podcast we feature DCAT Value Chain Insights’ Top 10 Watch List for Biologics and Biomanufacturing. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers) Vaccines: the…
Podcast 8: Facilitating Sourcing in the Wake of COVID-19
What measures are being taken by European Union authorities to mitigate potential shortages stemming from supply-chain and manufacturing disruptions? In this podcast we feature an article that outlines the guidance…
Podcast 7: COVID-19’s Impact on Global Pharma Supply Chains
What impact is COVID-19 having on pharmaceutical supply chains? In this podcast, we feature an article that reports on the concerns raised by industry groups, including reduced availability of international…
Podcast 6: Indian Government Looks to Increase Domestic API Manufacturing
In this podcast, we feature an article that looks at the Indian government’s $1.3-billion multi-year plan to increase domestic production of key starting materials and active pharmaceutical ingredients and its…
Podcast 5: Drug Supply Chains and US-Based Manufacturing
What does the global nature of the pharmaceutical supply chain mean for US policy? In this podcast, we feature an article that looks at proposals from members of Congress and…
